Clinical Trial Update: A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 study of sotorasib (Lumakras) for first-line treatment of stage IV KRAS p.G12C-mutant non-small cell lung cancer, with the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LUMAKRAS (sotorasib)

Snippet

Sponsor: Amgen | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED